Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

  Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences   Presentations to be Webcast on June 17, 2014 at 4:05 P.M. ET and June 25 at                                 10:30 A.M. ET  Wells Fargo Healthcare Conference 2014 JMP Securities Healthcare Conference 2014  Business Wire  WATERTOWN, Mass. -- June 10, 2014  Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview on Tuesday, June 17, 2014, at 4:05 p.m. ET during the Wells Fargo 2014 Healthcare Conference in Boston and on Wednesday, June 25, 2014 at 10:30 a.m. ET during the JMP Securities 9^th Annual Healthcare Conference in New York.  A live webcast and replay of each presentation can be accessed by visiting the “Calendar of Events” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of each webcast will be available following the presentation and will be archived for approximately 30 days.  About Enanta  Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.  Contact:  Investor Contact Enanta Pharmaceuticals, Inc. Carol Miceli, 617-607-0710 cmiceli@enanta.com  
Press spacebar to pause and continue. Press esc to stop.